ALLMedicine™ Hemolytic Anemia Center
Research & Reviews 3,929 results
https://www.ncbi.nlm.nih.gov/pubmed/33653793
Annals of Clinical and Laboratory Science; Jang W, Kim SK et. al.
Mar 3rd, 2021 - Hereditary spherocytosis (HS) is a congenital disorder of the red blood cell membrane and is characterized by hemolytic anemia, variable jaundice, and splenomegaly. In neonates, the diagnosis of HS can be difficult in the absence of family history...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909731
Journal of Thrombosis and Thrombolysis; Aggeli C, Polytarchou K et. al.
Feb 27th, 2021 - Sickle cell disease (SCD) is an inherited monogenic hemoglobinopathy characterized by formation of sickle erythrocytes under conditions of deoxygenation. Sickle erythrocytes can lead to thrombus formation and vaso-occlusive episodes that may resul...
https://doi.org/10.1532/hsf.3413
The Heart Surgery Forum; Huang JB, Wen ZK et. al.
Feb 26th, 2021 - Mitral repair has been widely used in the treatment of secondary mitral lesions in recent years. Hemolytic anemia is known to be a rare complication after mitral repair. This study aimed to investigate the diagnosis and treatment of mechanical hem...
https://doi.org/10.1182/blood.2020009849
Blood Wachter F, Archer NM
Feb 25th, 2021 - Autoimmune hemolytic anemia complicated by parvovirus infection.|2021|Wachter F,Archer NM,|
https://doi.org/10.1097/MOH.0000000000000642
Current Opinion in Hematology; El Nemer W, Godard A et. al.
Feb 25th, 2021 - Sickle cell disease (SCD) is a hemolytic anemia caused by a point mutation in the β globin gene leading to the expression of an abnormal hemoglobin (HbS) that polymerizes under hypoxic conditions driving red cell sickling. Circulating red cells ha...
Guidelines 11 results
http://investors.apellis.com/news-releases/news-release-details/apellis-apl-2-receives-orphan-drug-designation-fda-treatment
Feb 4th, 2019 - Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement ...
https://www.healio.com/hematology-oncology/hematology/news/online/%7B2785cd04-4008-4105-91cc-e82f5573ee6f%7D/fda-grants-orphan-drug-designation-to-apl-2-for-autoimmune-hemolytic-anemia
Feb 4th, 2019 - The FDA granted orphan drug designation to the C3 complement inhibitor APL-2 for the treatment of autoimmune hemolytic anemia. Autoimmune hemolytic anemia refers to both cold agglutinin disease and warm autoimmune hemolytic anemia, which affect a ...
https://www.nejm.org/doi/10.1056/NEJMoa1806311
Scully,M.,et al
Jan 23rd, 2019 - In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which re...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344868
American Journal of Hematology; Bianchi P, Fermo E et. al.
Oct 25th, 2018 - Pyruvate kinase deficiency (PKD) is the most common enzyme defect of glycolysis and an important cause of hereditary, nonspherocytic hemolytic anemia. The disease has a worldwide geographical distribution but there are no verified data regarding i...
https://doi.org/10.1007/s12185-017-2264-7
International Journal of Hematology; Matsumoto M, Fujimura Y et. al.
May 27th, 2017 - Thrombotic thrombocytopenic purpura (TTP) can rapidly progress into a life-threatening condition, thus the importance of appropriate diagnosis and treatment cannot be overstated. Until recently, TTP has mainly been diagnosed by clinical findings s...
Drugs 3 results see all →
Clinicaltrials.gov 3,995 results
https://www.ncbi.nlm.nih.gov/pubmed/33653793
Annals of Clinical and Laboratory Science; Jang W, Kim SK et. al.
Mar 3rd, 2021 - Hereditary spherocytosis (HS) is a congenital disorder of the red blood cell membrane and is characterized by hemolytic anemia, variable jaundice, and splenomegaly. In neonates, the diagnosis of HS can be difficult in the absence of family history...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909731
Journal of Thrombosis and Thrombolysis; Aggeli C, Polytarchou K et. al.
Feb 27th, 2021 - Sickle cell disease (SCD) is an inherited monogenic hemoglobinopathy characterized by formation of sickle erythrocytes under conditions of deoxygenation. Sickle erythrocytes can lead to thrombus formation and vaso-occlusive episodes that may resul...
https://doi.org/10.1532/hsf.3413
The Heart Surgery Forum; Huang JB, Wen ZK et. al.
Feb 26th, 2021 - Mitral repair has been widely used in the treatment of secondary mitral lesions in recent years. Hemolytic anemia is known to be a rare complication after mitral repair. This study aimed to investigate the diagnosis and treatment of mechanical hem...
https://doi.org/10.1182/blood.2020009849
Blood Wachter F, Archer NM
Feb 25th, 2021 - Autoimmune hemolytic anemia complicated by parvovirus infection.|2021|Wachter F,Archer NM,|
https://doi.org/10.1097/MOH.0000000000000642
Current Opinion in Hematology; El Nemer W, Godard A et. al.
Feb 25th, 2021 - Sickle cell disease (SCD) is a hemolytic anemia caused by a point mutation in the β globin gene leading to the expression of an abnormal hemoglobin (HbS) that polymerizes under hypoxic conditions driving red cell sickling. Circulating red cells ha...
News 133 results
https://reference.medscape.com/viewarticle/924856
Nov 1st, 2020 - Each year worldwide, as many as 400,000 individuals are born with sickle cell disease (SCD). SCD is a life-threatening hematologic disorder in which there is a disruption of blood flow in small vessels; this vaso-occlusion leads to distal tissue i...
https://www.medscape.com/viewarticle/892693_2
Oct 29th, 2020 - Pyruvate kinase deficiency is an inherited metabolic disorder of the enzyme pyruvate kinase, which affects the survival of erythrocytes. Both autosomal dominant and recessive inheritance have been observed with the disorder; classically, and more ...
https://www.mdedge.com/hematology-oncology/article/214191/anemia/sutimlimab-boosts-hemoglobin-quality-life-cold-agglutinin?channel=39313
Neil Osterweil
Dec 12th, 2019 - ORLANDO – An investigational selective inhibitor of the complement pathway, sutimlimab, induced rapid and sustained benefits in patients with cold agglutinin disease, a rare autoimmune hemolytic anemia with no currently approved effective therapie.
https://www.mdedge.com/hematology-oncology/article/210264/anemia/autoimmune-hemolytic-anemia-evaluation-and-diagnosis/page/0/3?channel=182
Oct 18th, 2019 - Transfusion Therapy Performing transfusions can be very difficult in patients with AIHA. 2 The presence of the autoantibody can interfere with typing of the blood and almost always interferes with the crossmatch, since this final step consists of m.
https://www.mdedge.com/hematology-oncology/article/210272/anemia/autoimmune-hemolytic-anemia-treatment-common-types/page/0/4?channel=182
Oct 18th, 2019 - Drug-Induced Hemolytic Anemia AIHA caused by a drug reaction is rare, with a lower incidence than drug-related ITP. The rate of severe drug-related AIHA is estimated at 1:1,000,000, but less severe cases may be missed.